Synthesis of Chitosan Based Nanocomposite with 3-(2-(3,4- dimethoxyphenyl)-2-oxoethylidene) indolin-2-one (RAJI) for Efficient Therapy Against Triple Negative Breast Cancer

Cancer is defined by the unregulated and excessive growth of abnormal cells, eventually leading to the destruction of body tissues. Among various cancer types, breast cancer is notably prevalent in females generally originating in the ducts or lobules forming lumps or tumours and subsequently metastasizing to other regions of the body. The treatment of breast cancer is contingent upon its stage and typically involves surgery, chemotherapy, radiation, hormone therapy, etc. Drugs currently available on the market frequently induce substantial adverse effects, which has prompted the development of innovative therapeutic agents. In this study, we propose the use of a novel compound, 3-(2-(3,4-dimethoxyphenyl)-2- oxoethylidene) indolin-2-one (RAJI), with chitosan to create a nanocomposite for the purpose of developing an effective breast cancer treatment. RAJI-loaded chitosan nanocomposite was synthesized using a high-pressure homogenizer and subsequently characterized to assess their physicochemical properties and drug loading profile. The In-vitro toxicity analyses of RAJI on MDA-MB-231 cells - a Triple Negative Breast Cancer (TNBC) cell line, demonstrated its potent anticancer properties. Consequently, we speculate that the efficaciousness of RAJI-loaded chitosan nanocomposite in the treatment of TNBC will be superior to that of other commercially available medicines.